Pharmacologic Substance – Page 189

Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment

2 years ago talkbio0Tagged Amylyx, Amyotrophic Lateral Sclerosis, Clinical Research, Clinical Trials, Failure (biologic function), Phoenix Pharmaceuticals, Relyvrio

Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals

Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing

2 years ago talkbio0Tagged Caplyta, CGI-S, Clinical Global Impression Original Version Questionnaire, clinically, File (record), Intra-Cellular Therapies, Lumateperone, MADRS, MDD, Montgomery-Åsberg depression rating scale, Phase 3 trial, Positive, results, Severities, Statistical Significance, Unipolar Depression, United States Food and Drug Administration

Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing

Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

2 years ago talkbio0Tagged 2032, APOC3 gene, Arrowhead, cellular targeting, Dyslipidemias, Familial chylomicronemia syndrome, FCS, Fetal Bovine Serum, GlobalData, Plozasiran, Projections and Predictions, Sales - occupational activity, SHTG, Triglycerides, Unmet Needs

Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia

Intra-Cellular’s Caplyta Shows Promising Results in Major Depressive Disorder Study

2 years ago talkbio0Tagged adjunctive therapy, blockbuster label, Caplyta, Clinical Global Impression Original Version Questionnaire, expansion, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, MDD, Montgomery-Åsberg depression rating scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Positive Clinical Trial, Study 501, Unipolar Depression

Intra-Cellular Therapies, Caplyta (lumateperone), Major Depressive Disorder (MDD), Positive clinical trial results, Study 501, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale, Adjunctive therapy, Potential blockbuster label expansion

Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade

2 years ago talkbio0Tagged Administration occupational activities, approvals, boehringer ingelheim, Decade, expansion, Heart failure, Jardiance, late-stage pipeline, launches, pipeline, reshuffle

Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle

Novartis’ Fabhalta (Iptacopan) Receives FDA Priority Review for IgA Nephropathy (IgAN) Treatment

2 years ago talkbio0Tagged Fabhalta, IGA Glomerulonephritis, Iptacopan, Novartis, Phase 3, Priority Review, United States Food and Drug Administration

Novartis, Fabhalta, Iptacopan, IgA Nephropathy (IgAN), FDA Priority Review, Phase 3 Data

Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits

2 years ago talkbio0Tagged Neumora, NMRA-266, Schizophrenia, Seizures, United States Food and Drug Administration

Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia

EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts

2 years ago talkbio0Tagged European Medicines Agency, Evaluation, Feeling suicidal (finding), Glucagon-Like Peptide 1, Ozempic, Wegovy

GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation

AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11

2 years ago talkbio0Tagged Age, Approved, AstraZeneca, benralizumab, Child, expansion, Fasenra, Pediatric Label, Severe asthma, United States Food and Drug Administration

AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11

Eli Lilly’s State Law Attempt to Halt Florida Compounding Pharmacy’s Tirzepatide Sales Dismissed

2 years ago talkbio0Tagged Cosmetic Act, eli lilly, FDCA, Florida compounding pharmacy, Frivolous lawsuits, Judge Roy Altman, Mounjaro/ Zepbound, RXCompoundStore.com, tirzepatide

Eli Lilly, Florida compounding pharmacy, RXCompoundStore.com, Tirzepatide (Mounjaro/ Zepbound), Judge Roy Altman, Federal Food/ Drug/ and Cosmetic Act (FDCA), Frivolous lawsuits